Global Gene Therapy for Age-related Macular Degeneration Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Description

Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.

According to our (Global Info Research) latest study, the global Gene Therapy for Age-related Macular Degeneration market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the market's growth.

This report is a detailed and comprehensive analysis for global Gene Therapy for Age-related Macular Degeneration market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Gene Therapy for Age-related Macular Degeneration market size and forecasts, in consumption value ($ Million), 2018-2029
Global Gene Therapy for Age-related Macular Degeneration market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Gene Therapy for Age-related Macular Degeneration market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Gene Therapy for Age-related Macular Degeneration market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Gene Therapy for Age-related Macular Degeneration
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Gene Therapy for Age-related Macular Degeneration market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include RetroSense Therapeutics, REGENXBIO and AGTC. etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Gene Therapy for Age-related Macular Degeneration market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Subretinal
    Intravitreal

Market segment by Application
    Monotherapy
    Combination Therapy

Market segment by players, this report covers
    RetroSense Therapeutics
    REGENXBIO
    AGTC

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Gene Therapy for Age-related Macular Degeneration product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Gene Therapy for Age-related Macular Degeneration, with revenue, gross margin and global market share of Gene Therapy for Age-related Macular Degeneration from 2018 to 2023.
Chapter 3, the Gene Therapy for Age-related Macular Degeneration competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Gene Therapy for Age-related Macular Degeneration market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Gene Therapy for Age-related Macular Degeneration.
Chapter 13, to describe Gene Therapy for Age-related Macular Degeneration research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Gene Therapy for Age-related Macular Degeneration
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Gene Therapy for Age-related Macular Degeneration by Type
        1.3.1 Overview: Global Gene Therapy for Age-related Macular Degeneration Market Size by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Global Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Type in 2022
        1.3.3 Subretinal
        1.3.4 Intravitreal
    1.4 Global Gene Therapy for Age-related Macular Degeneration Market by Application
        1.4.1 Overview: Global Gene Therapy for Age-related Macular Degeneration Market Size by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Monotherapy
        1.4.3 Combination Therapy
    1.5 Global Gene Therapy for Age-related Macular Degeneration Market Size & Forecast
    1.6 Global Gene Therapy for Age-related Macular Degeneration Market Size and Forecast by Region
        1.6.1 Global Gene Therapy for Age-related Macular Degeneration Market Size by Region: 2018 VS 2022 VS 2029
        1.6.2 Global Gene Therapy for Age-related Macular Degeneration Market Size by Region, (2018-2029)
        1.6.3 North America Gene Therapy for Age-related Macular Degeneration Market Size and Prospect (2018-2029)
        1.6.4 Europe Gene Therapy for Age-related Macular Degeneration Market Size and Prospect (2018-2029)
        1.6.5 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size and Prospect (2018-2029)
        1.6.6 South America Gene Therapy for Age-related Macular Degeneration Market Size and Prospect (2018-2029)
        1.6.7 Middle East and Africa Gene Therapy for Age-related Macular Degeneration Market Size and Prospect (2018-2029)

2 Company Profiles
    2.1 RetroSense Therapeutics
        2.1.1 RetroSense Therapeutics Details
        2.1.2 RetroSense Therapeutics Major Business
        2.1.3 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Product and Solutions
        2.1.4 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 RetroSense Therapeutics Recent Developments and Future Plans
    2.2 REGENXBIO
        2.2.1 REGENXBIO Details
        2.2.2 REGENXBIO Major Business
        2.2.3 REGENXBIO Gene Therapy for Age-related Macular Degeneration Product and Solutions
        2.2.4 REGENXBIO Gene Therapy for Age-related Macular Degeneration Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 REGENXBIO Recent Developments and Future Plans
    2.3 AGTC
        2.3.1 AGTC Details
        2.3.2 AGTC Major Business
        2.3.3 AGTC Gene Therapy for Age-related Macular Degeneration Product and Solutions
        2.3.4 AGTC Gene Therapy for Age-related Macular Degeneration Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 AGTC Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Gene Therapy for Age-related Macular Degeneration Revenue and Share by Players (2018-2023)
    3.2 Market Share Analysis (2022)
        3.2.1 Market Share of Gene Therapy for Age-related Macular Degeneration by Company Revenue
        3.2.2 Top 3 Gene Therapy for Age-related Macular Degeneration Players Market Share in 2022
        3.2.3 Top 6 Gene Therapy for Age-related Macular Degeneration Players Market Share in 2022
    3.3 Gene Therapy for Age-related Macular Degeneration Market: Overall Company Footprint Analysis
        3.3.1 Gene Therapy for Age-related Macular Degeneration Market: Region Footprint
        3.3.2 Gene Therapy for Age-related Macular Degeneration Market: Company Product Type Footprint
        3.3.3 Gene Therapy for Age-related Macular Degeneration Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Gene Therapy for Age-related Macular Degeneration Consumption Value and Market Share by Type (2018-2023)
    4.2 Global Gene Therapy for Age-related Macular Degeneration Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
    5.1 Global Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Application (2018-2023)
    5.2 Global Gene Therapy for Age-related Macular Degeneration Market Forecast by Application (2024-2029)

6 North America
    6.1 North America Gene Therapy for Age-related Macular Degeneration Consumption Value by Type (2018-2029)
    6.2 North America Gene Therapy for Age-related Macular Degeneration Consumption Value by Application (2018-2029)
    6.3 North America Gene Therapy for Age-related Macular Degeneration Market Size by Country
        6.3.1 North America Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2018-2029)
        6.3.2 United States Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)
        6.3.3 Canada Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)
        6.3.4 Mexico Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)

7 Europe
    7.1 Europe Gene Therapy for Age-related Macular Degeneration Consumption Value by Type (2018-2029)
    7.2 Europe Gene Therapy for Age-related Macular Degeneration Consumption Value by Application (2018-2029)
    7.3 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country
        7.3.1 Europe Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2018-2029)
        7.3.2 Germany Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)
        7.3.3 France Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)
        7.3.4 United Kingdom Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)
        7.3.5 Russia Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)
        7.3.6 Italy Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)

8 Asia-Pacific
    8.1 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption Value by Type (2018-2029)
    8.2 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption Value by Application (2018-2029)
    8.3 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region
        8.3.1 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption Value by Region (2018-2029)
        8.3.2 China Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)
        8.3.3 Japan Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)
        8.3.4 South Korea Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)
        8.3.5 India Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)
        8.3.6 Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)
        8.3.7 Australia Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)

9 South America
    9.1 South America Gene Therapy for Age-related Macular Degeneration Consumption Value by Type (2018-2029)
    9.2 South America Gene Therapy for Age-related Macular Degeneration Consumption Value by Application (2018-2029)
    9.3 South America Gene Therapy for Age-related Macular Degeneration Market Size by Country
        9.3.1 South America Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2018-2029)
        9.3.2 Brazil Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)
        9.3.3 Argentina Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)

10 Middle East & Africa
    10.1 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Consumption Value by Type (2018-2029)
    10.2 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Consumption Value by Application (2018-2029)
    10.3 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country
        10.3.1 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2018-2029)
        10.3.2 Turkey Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)
        10.3.3 Saudi Arabia Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)
        10.3.4 UAE Gene Therapy for Age-related Macular Degeneration Market Size and Forecast (2018-2029)

11 Market Dynamics
    11.1 Gene Therapy for Age-related Macular Degeneration Market Drivers
    11.2 Gene Therapy for Age-related Macular Degeneration Market Restraints
    11.3 Gene Therapy for Age-related Macular Degeneration Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry
    11.5 Influence of COVID-19 and Russia-Ukraine War
        11.5.1 Influence of COVID-19
        11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
    12.1 Gene Therapy for Age-related Macular Degeneration Industry Chain
    12.2 Gene Therapy for Age-related Macular Degeneration Upstream Analysis
    12.3 Gene Therapy for Age-related Macular Degeneration Midstream Analysis
    12.4 Gene Therapy for Age-related Macular Degeneration Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Gene Therapy for Age-related Macular Degeneration Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Gene Therapy for Age-related Macular Degeneration Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Global Gene Therapy for Age-related Macular Degeneration Consumption Value by Region (2018-2023) & (USD Million)
    Table 4. Global Gene Therapy for Age-related Macular Degeneration Consumption Value by Region (2024-2029) & (USD Million)
    Table 5. RetroSense Therapeutics Company Information, Head Office, and Major Competitors
    Table 6. RetroSense Therapeutics Major Business
    Table 7. RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Product and Solutions
    Table 8. RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 9. RetroSense Therapeutics Recent Developments and Future Plans
    Table 10. REGENXBIO Company Information, Head Office, and Major Competitors
    Table 11. REGENXBIO Major Business
    Table 12. REGENXBIO Gene Therapy for Age-related Macular Degeneration Product and Solutions
    Table 13. REGENXBIO Gene Therapy for Age-related Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 14. REGENXBIO Recent Developments and Future Plans
    Table 15. AGTC Company Information, Head Office, and Major Competitors
    Table 16. AGTC Major Business
    Table 17. AGTC Gene Therapy for Age-related Macular Degeneration Product and Solutions
    Table 18. AGTC Gene Therapy for Age-related Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 19. AGTC Recent Developments and Future Plans
    Table 20. Global Gene Therapy for Age-related Macular Degeneration Revenue (USD Million) by Players (2018-2023)
    Table 21. Global Gene Therapy for Age-related Macular Degeneration Revenue Share by Players (2018-2023)
    Table 22. Breakdown of Gene Therapy for Age-related Macular Degeneration by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 23. Market Position of Players in Gene Therapy for Age-related Macular Degeneration, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
    Table 24. Head Office of Key Gene Therapy for Age-related Macular Degeneration Players
    Table 25. Gene Therapy for Age-related Macular Degeneration Market: Company Product Type Footprint
    Table 26. Gene Therapy for Age-related Macular Degeneration Market: Company Product Application Footprint
    Table 27. Gene Therapy for Age-related Macular Degeneration New Market Entrants and Barriers to Market Entry
    Table 28. Gene Therapy for Age-related Macular Degeneration Mergers, Acquisition, Agreements, and Collaborations
    Table 29. Global Gene Therapy for Age-related Macular Degeneration Consumption Value (USD Million) by Type (2018-2023)
    Table 30. Global Gene Therapy for Age-related Macular Degeneration Consumption Value Share by Type (2018-2023)
    Table 31. Global Gene Therapy for Age-related Macular Degeneration Consumption Value Forecast by Type (2024-2029)
    Table 32. Global Gene Therapy for Age-related Macular Degeneration Consumption Value by Application (2018-2023)
    Table 33. Global Gene Therapy for Age-related Macular Degeneration Consumption Value Forecast by Application (2024-2029)
    Table 34. North America Gene Therapy for Age-related Macular Degeneration Consumption Value by Type (2018-2023) & (USD Million)
    Table 35. North America Gene Therapy for Age-related Macular Degeneration Consumption Value by Type (2024-2029) & (USD Million)
    Table 36. North America Gene Therapy for Age-related Macular Degeneration Consumption Value by Application (2018-2023) & (USD Million)
    Table 37. North America Gene Therapy for Age-related Macular Degeneration Consumption Value by Application (2024-2029) & (USD Million)
    Table 38. North America Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2018-2023) & (USD Million)
    Table 39. North America Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2024-2029) & (USD Million)
    Table 40. Europe Gene Therapy for Age-related Macular Degeneration Consumption Value by Type (2018-2023) & (USD Million)
    Table 41. Europe Gene Therapy for Age-related Macular Degeneration Consumption Value by Type (2024-2029) & (USD Million)
    Table 42. Europe Gene Therapy for Age-related Macular Degeneration Consumption Value by Application (2018-2023) & (USD Million)
    Table 43. Europe Gene Therapy for Age-related Macular Degeneration Consumption Value by Application (2024-2029) & (USD Million)
    Table 44. Europe Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2018-2023) & (USD Million)
    Table 45. Europe Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2024-2029) & (USD Million)
    Table 46. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption Value by Type (2018-2023) & (USD Million)
    Table 47. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption Value by Type (2024-2029) & (USD Million)
    Table 48. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption Value by Application (2018-2023) & (USD Million)
    Table 49. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption Value by Application (2024-2029) & (USD Million)
    Table 50. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption Value by Region (2018-2023) & (USD Million)
    Table 51. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption Value by Region (2024-2029) & (USD Million)
    Table 52. South America Gene Therapy for Age-related Macular Degeneration Consumption Value by Type (2018-2023) & (USD Million)
    Table 53. South America Gene Therapy for Age-related Macular Degeneration Consumption Value by Type (2024-2029) & (USD Million)
    Table 54. South America Gene Therapy for Age-related Macular Degeneration Consumption Value by Application (2018-2023) & (USD Million)
    Table 55. South America Gene Therapy for Age-related Macular Degeneration Consumption Value by Application (2024-2029) & (USD Million)
    Table 56. South America Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2018-2023) & (USD Million)
    Table 57. South America Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2024-2029) & (USD Million)
    Table 58. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Consumption Value by Type (2018-2023) & (USD Million)
    Table 59. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Consumption Value by Type (2024-2029) & (USD Million)
    Table 60. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Consumption Value by Application (2018-2023) & (USD Million)
    Table 61. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Consumption Value by Application (2024-2029) & (USD Million)
    Table 62. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2018-2023) & (USD Million)
    Table 63. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2024-2029) & (USD Million)
    Table 64. Gene Therapy for Age-related Macular Degeneration Raw Material
    Table 65. Key Suppliers of Gene Therapy for Age-related Macular Degeneration Raw Materials
List of Figures
    Figure 1. Gene Therapy for Age-related Macular Degeneration Picture
    Figure 2. Global Gene Therapy for Age-related Macular Degeneration Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Type in 2022
    Figure 4. Subretinal
    Figure 5. Intravitreal
    Figure 6. Global Gene Therapy for Age-related Macular Degeneration Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 7. Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Application in 2022
    Figure 8. Monotherapy Picture
    Figure 9. Combination Therapy Picture
    Figure 10. Global Gene Therapy for Age-related Macular Degeneration Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 11. Global Gene Therapy for Age-related Macular Degeneration Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 12. Global Market Gene Therapy for Age-related Macular Degeneration Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
    Figure 13. Global Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Region (2018-2029)
    Figure 14. Global Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Region in 2022
    Figure 15. North America Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 16. Europe Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 17. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 18. South America Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 19. Middle East and Africa Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 20. Global Gene Therapy for Age-related Macular Degeneration Revenue Share by Players in 2022
    Figure 21. Gene Therapy for Age-related Macular Degeneration Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
    Figure 22. Global Top 3 Players Gene Therapy for Age-related Macular Degeneration Market Share in 2022
    Figure 23. Global Top 6 Players Gene Therapy for Age-related Macular Degeneration Market Share in 2022
    Figure 24. Global Gene Therapy for Age-related Macular Degeneration Consumption Value Share by Type (2018-2023)
    Figure 25. Global Gene Therapy for Age-related Macular Degeneration Market Share Forecast by Type (2024-2029)
    Figure 26. Global Gene Therapy for Age-related Macular Degeneration Consumption Value Share by Application (2018-2023)
    Figure 27. Global Gene Therapy for Age-related Macular Degeneration Market Share Forecast by Application (2024-2029)
    Figure 28. North America Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Type (2018-2029)
    Figure 29. North America Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Application (2018-2029)
    Figure 30. North America Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Country (2018-2029)
    Figure 31. United States Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 32. Canada Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 33. Mexico Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 34. Europe Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Type (2018-2029)
    Figure 35. Europe Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Application (2018-2029)
    Figure 36. Europe Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Country (2018-2029)
    Figure 37. Germany Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 38. France Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 39. United Kingdom Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 40. Russia Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 41. Italy Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 42. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Type (2018-2029)
    Figure 43. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Application (2018-2029)
    Figure 44. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Region (2018-2029)
    Figure 45. China Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 46. Japan Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 47. South Korea Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 48. India Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 49. Southeast Asia Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 50. Australia Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 51. South America Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Type (2018-2029)
    Figure 52. South America Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Application (2018-2029)
    Figure 53. South America Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Country (2018-2029)
    Figure 54. Brazil Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 55. Argentina Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 56. Middle East and Africa Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Type (2018-2029)
    Figure 57. Middle East and Africa Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Application (2018-2029)
    Figure 58. Middle East and Africa Gene Therapy for Age-related Macular Degeneration Consumption Value Market Share by Country (2018-2029)
    Figure 59. Turkey Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 60. Saudi Arabia Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 61. UAE Gene Therapy for Age-related Macular Degeneration Consumption Value (2018-2029) & (USD Million)
    Figure 62. Gene Therapy for Age-related Macular Degeneration Market Drivers
    Figure 63. Gene Therapy for Age-related Macular Degeneration Market Restraints
    Figure 64. Gene Therapy for Age-related Macular Degeneration Market Trends
    Figure 65. Porters Five Forces Analysis
    Figure 66. Manufacturing Cost Structure Analysis of Gene Therapy for Age-related Macular Degeneration in 2022
    Figure 67. Manufacturing Process Analysis of Gene Therapy for Age-related Macular Degeneration
    Figure 68. Gene Therapy for Age-related Macular Degeneration Industrial Chain
    Figure 69. Methodology
    Figure 70. Research Process and Data Source

Companies Mentioned

RetroSense Therapeutics
REGENXBIO
AGTC